This brand name is authorized in Germany, Spain
The drug TRANXILIUM contains one active pharmaceutical ingredient (API):
|
1
Clorazepate
UNII 63FN7G03XY - CLORAZEPATE DIPOTASSIUM
|
|
Clorazepate is a benzodiazepine with anxiolytic, sedative, hypnotic, and anticonvulsant properties. Clorazepate exerts its effect by de-activating the nervous system through potentiation of the inhibitory effect of gamma-aminobutyric acid (GABA) on the GABA-A receptors by binding to a site that is distinct from the GABA binding site. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N05BA05 | Potassium clorazepate | N Nervous system → N05 Psycholeptics → N05B Anxiolytics → N05BA Benzodiazepine derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: DE | Bundesinstitut für Arzneimittel und Medizinprodukte | Identifier(s): 01330337, 01330366, 01330372, 01659942, 01659959, 03073471, 03073488 |
| Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 48985, 48986, 51378, 52112, 55689 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
